Matteo Biagetti

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists
    Matteo Biagetti
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:4741-4. 2010
  2. ncbi The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists
    Gillian E Lunniss
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Harlow, UK
    Bioorg Med Chem Lett 20:7341-4. 2010
  3. ncbi Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists
    Domenica Antonia Pizzi
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:7120-3. 2010
  4. ncbi Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists
    Colin P Leslie
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:6103-7. 2010
  5. ncbi The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists
    Gillian E Lunniss
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Harlow, UK
    Bioorg Med Chem Lett 19:4022-5. 2009

Collaborators

Detail Information

Publications5

  1. ncbi Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists
    Matteo Biagetti
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:4741-4. 2010
    ..1.0]hexane scaffold was identified through modification of a screening hit. Structure-activity relationships and efforts undertaken to achieve a favourable pharmacokinetic profile in rat are described...
  2. ncbi The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists
    Gillian E Lunniss
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Harlow, UK
    Bioorg Med Chem Lett 20:7341-4. 2010
    ..The identification and subsequent optimisation of a selective non-peptidic NPY Y2 antagonist series is described. This led to the development of amine 2, a selective, soluble NPY Y2 receptor antagonist with enhanced CNS exposure...
  3. ncbi Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists
    Domenica Antonia Pizzi
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:7120-3. 2010
    ..Optimisation led to the identification of the brain penetrant, orally bioavailable Y5 antagonist 9b which significantly inhibited the food intake induced by a Y5 selective agonist with a minimal effective dose of 30mg/kg po...
  4. ncbi Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists
    Colin P Leslie
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Verona, Italy
    Bioorg Med Chem Lett 20:6103-7. 2010
    ..Both compounds significantly inhibited the food intake induced by a Y5 selective agonist with minimal effective doses of 3mg/kg po...
  5. ncbi The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists
    Gillian E Lunniss
    GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Harlow, UK
    Bioorg Med Chem Lett 19:4022-5. 2009
    ..A subsequent SAR study and optimisation programme based around this molecule is also described, leading to the identification of potent and soluble pyridyl analogue 36...